argenx SE
phase trial in pemphigus focus on potential to drive fast onset and steroid sparing address | argenx SE
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
10 of 20
Similar slides by argenx SE
See diffirences between slides (animation)
Investor Presentation
December 2023
address | argenx SE
Investor Presentation
November 2023
pemphigus address trial topline data expected around | argenx SE
Results
October 2023
pemphigus address trial | argenx SE
Investor Presentation
August 2023
pemphigus address trial focus on fast onset and steroid sparing extension study | argenx SE
Related slides by other companies
OKYO Pharma
Results
June 2023
phase trial design rota | OKYO Pharma
RenovoRx
IPO
August 2021
designed for success one phase trial to approval pivotal tiger pac phase study schema currently enrolling | RenovoRx
Erasca
Investor Presentation
August 2023
proposed pivotal phase trial designs creative strategy includes high randomized melanoma trial and tissue agnostic indication | Erasca
Theravance Biopharma
Results
May 2023
progress against targets | Theravance Biopharma
Other recent decks by argenx SE
See all presentations (28 decks)
Results
February 2024
Investor Conference
January 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights